{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:46:21Z","timestamp":1790826381808,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T00:00:00Z","timestamp":1573430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012091","name":"NIHR Clinical Research Network Thames Valley and South Midlands","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012091","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009342","name":"Aeras Global Tuberculosis Vaccine Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009342","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.vaccine.2019.10.102","type":"journal-article","created":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T01:28:46Z","timestamp":1573781326000},"page":"779-789","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":92,"title":["A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime \u2013 MVA85A boost in healthy UK adults"],"prefix":"10.1016","volume":"38","author":[{"given":"Morven","family":"Wilkie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Satti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Minhinnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Riste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel Lopez","family":"Ramon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Sheehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zita-Rose Manjaly","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Stockdale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hamidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew K.","family":"O'Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kritica","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah Michaela","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Davenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Morton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Vermaak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Lawrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6895-1967","authenticated-orcid":false,"given":"Paul","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2126-5142","authenticated-orcid":false,"given":"Helen","family":"McShane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.10.102_b0005","unstructured":"WHO, Global tuberculosis report 2016; 2017."},{"key":"10.1016\/j.vaccine.2019.10.102_b0010","unstructured":"The Global Plan to End TB: The Paradigm Shift 2016\u20132020. Stop TB Partnership; 2016."},{"issue":"9","key":"10.1016\/j.vaccine.2019.10.102_b0015","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jama.1994.03510330076038","article-title":"Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature","volume":"271","author":"Colditz","year":"1994","journal-title":"JAMA"},{"issue":"9517","key":"10.1016\/j.vaccine.2019.10.102_b0020","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(06)68507-3","article-title":"Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness","volume":"367","author":"Trunz","year":"2006","journal-title":"The Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2019.10.102_b0025","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/ije\/22.6.1154","article-title":"Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis","volume":"22","author":"Rodrigues","year":"1993","journal-title":"Int J Epidemiol"},{"issue":"1","key":"10.1016\/j.vaccine.2019.10.102_b0030","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.tube.2004.09.015","article-title":"Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials","volume":"85","author":"McShane","year":"2005","journal-title":"Tuberculosis"},{"issue":"4","key":"10.1016\/j.vaccine.2019.10.102_b0035","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1586\/14760584.6.4.539","article-title":"Heterologous boost vaccines for bacillus Calmette-Gu\u00e9rin prime immunization against tuberculosis","volume":"6","author":"Xing","year":"2007","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2019.10.102_b0040","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2567.2004.01903.x","article-title":"Cellular immune responses induced in cattle by heterologous prime\u2013boost vaccination using recombinant viruses and bacille Calmette-Gu\u00e9rin","volume":"112","author":"Vordermeier","year":"2004","journal-title":"Immunology"},{"issue":"2","key":"10.1016\/j.vaccine.2019.10.102_b0045","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1128\/IAI.74.2.1416-1418.2006","article-title":"Immune responses induced in cattle by vaccination with a recombinant adenovirus expressing mycobacterial antigen 85A and mycobacterium bovis BCG","volume":"74","author":"Vordermeier","year":"2006","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.vaccine.2019.10.102_b0050","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1128\/IAI.69.2.681-686.2001","article-title":"Enhanced immunogenicity of CD4+ T-Cell responses and protective efficacy of a DNA-modified vaccinia virus ankara prime-boost vaccination regimen for murine tuberculosis","volume":"69","author":"McShane","year":"2001","journal-title":"Infect Immun"},{"issue":"9871","key":"10.1016\/j.vaccine.2019.10.102_b0055","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial","volume":"381","author":"Tameris","year":"2013","journal-title":"The Lancet"},{"issue":"286","key":"10.1016\/j.vaccine.2019.10.102_b0060","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa2373","article-title":"Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults","volume":"7","author":"Ogwang","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2019.10.102_b0065","first-page":"2836","volume":"4","author":"Ewer","year":"2013","journal-title":"Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation"},{"issue":"11","key":"10.1016\/j.vaccine.2019.10.102_b0070","doi-asserted-by":"crossref","first-page":"e0141687","DOI":"10.1371\/journal.pone.0141687","article-title":"A phase I, open-label trial, evaluating the safety and immunogenicity of candidate tuberculosis vaccines AERAS-402 and MVA85A, administered by prime-boost regime in BCG-vaccinated healthy adults","volume":"10","author":"Sheehan","year":"2015","journal-title":"PLoS ONE"},{"issue":"17","key":"10.1016\/j.vaccine.2019.10.102_b0075","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1803484","article-title":"Phase 2b controlled trial of M72\/AS01E vaccine to prevent tuberculosis","volume":"379","author":"Van Der Meeren","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.vaccine.2019.10.102_b0080","doi-asserted-by":"crossref","first-page":"e40385","DOI":"10.1371\/journal.pone.0040385","article-title":"A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity","volume":"7","author":"Dicks","year":"2012","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.vaccine.2019.10.102_b0085","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/mt.2013.284","article-title":"Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens","volume":"22","author":"Antrobus","year":"2014","journal-title":"Mol Ther"},{"issue":"48","key":"10.1016\/j.vaccine.2019.10.102_b0090","doi-asserted-by":"crossref","first-page":"6800","DOI":"10.1016\/j.vaccine.2015.10.017","article-title":"Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A","volume":"33","author":"Stylianou","year":"2015","journal-title":"Vaccine"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2019.10.102_b0095","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jim.2004.06.010","article-title":"Novel application of a whole blood intracellular cytokine detection assay to quantitate specific T-cell frequency in field studies","volume":"291","author":"Hanekom","year":"2004","journal-title":"J Immunol Methods"},{"issue":"7","key":"10.1016\/j.vaccine.2019.10.102_b0100","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.vaccine.2012.12.042","article-title":"Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery","volume":"31","author":"Meyer","year":"2013","journal-title":"Vaccine"},{"issue":"26","key":"10.1016\/j.vaccine.2019.10.102_b0105","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1056\/NEJM199612263352604","article-title":"Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection","volume":"335","author":"Jouanguy","year":"1996","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.vaccine.2019.10.102_b0110","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJM199612263352602","article-title":"A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection","volume":"335","author":"Newport","year":"1996","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2019.10.102_b0115","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1084\/jem.178.6.2249","article-title":"An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection","volume":"178","author":"Flynn","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2019.10.102_b0120","doi-asserted-by":"crossref","first-page":"11290","DOI":"10.1038\/ncomms11290","article-title":"T-cell activation is an immune correlate of risk in BCG vaccinated infants","volume":"7","author":"Fletcher","year":"2016","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.vaccine.2019.10.102_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2010.04146.x","article-title":"How tumour necrosis factor blockers interfere with tuberculosis immunity","volume":"161","author":"Harris","year":"2010","journal-title":"Clin Exp Immunol"},{"issue":"4856","key":"10.1016\/j.vaccine.2019.10.102_b0130","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1126\/science.3131876","article-title":"Interleukin-2: inception, impact, and implications","volume":"240","author":"Smith","year":"1988","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.vaccine.2019.10.102_b0135","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/ni1449","article-title":"IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge","volume":"8","author":"Khader","year":"2007","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2019.10.102_b0140","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1086\/648735","article-title":"Regulatory T cells modulate Th17 responses in patients with positive tuberculin skin test results","volume":"201","author":"Babu","year":"2010","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2019.10.102_b0145","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1164\/rccm.200306-837OC","article-title":"Mycobacterium tuberculosis-specific CD8+ T cells preferentially recognize heavily infected cells","volume":"168","author":"Lewinsohn","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.vaccine.2019.10.102_b0150","doi-asserted-by":"crossref","first-page":"e1000392","DOI":"10.1371\/journal.ppat.1000392","article-title":"A critical role for CD8 T cells in a nonhuman primate model of tuberculosis","volume":"5","author":"Chen","year":"2009","journal-title":"PLoS Pathog"},{"issue":"8","key":"10.1016\/j.vaccine.2019.10.102_b0155","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1073\/pnas.97.8.4204","article-title":"Relative contributions of distinct MHC class I-dependent cell populations in protection to tuberculosis infection in mice","volume":"97","author":"Sousa","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"issue":"15","key":"10.1016\/j.vaccine.2019.10.102_b0160","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and immunogenicity of novel adenovirus type 26\u2013 and modified vaccinia ankara\u2013vectored ebola vaccines: a randomized clinical trial","volume":"315","author":"Milligan","year":"2016","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.vaccine.2019.10.102_b0165","doi-asserted-by":"crossref","first-page":"e31208","DOI":"10.1371\/journal.pone.0031208","article-title":"Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors","volume":"7","author":"Sheehy","year":"2012","journal-title":"PLoS ONE"},{"issue":"17","key":"10.1016\/j.vaccine.2019.10.102_b0170","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","article-title":"A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA","volume":"374","author":"Ewer","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.vaccine.2019.10.102_b0175","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1002\/eji.200737504","article-title":"Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations","volume":"37","author":"Beveridge","year":"2007","journal-title":"Eur J Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2019.10.102_b0180","doi-asserted-by":"crossref","first-page":"8047","DOI":"10.4049\/jimmunol.0801592","article-title":"Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells","volume":"182","author":"Lindenstrom","year":"2009","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2019.10.102_b0185","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nm1592","article-title":"Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major","volume":"13","author":"Darrah","year":"2007","journal-title":"Nat Med"},{"issue":"Pt 1","key":"10.1016\/j.vaccine.2019.10.102_b0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/mic.0.049601-0","article-title":"Pre-existing immunity against vaccine vectors\u2013friend or foe?","volume":"159","author":"Saxena","year":"2013","journal-title":"Microbiology"},{"key":"10.1016\/j.vaccine.2019.10.102_b0195","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.tube.2016.08.001","article-title":"Antibodies and tuberculosis","volume":"101","author":"Jacobs","year":"2016","journal-title":"Tuberculosis (Edinb)"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1931504X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1931504X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:38:46Z","timestamp":1759401526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1931504X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0264410X1931504X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.10.102","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime \u2013 MVA85A boost in healthy UK adults","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.10.102","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}